Overview

Pilot Study of the Safety and Efficacy of Sulfasalazine in Pulmonary Arterial Hypertension

Status:
Recruiting
Trial end date:
2022-10-31
Target enrollment:
Participant gender:
Summary
Under placebo control, the investigators intend to evaluate the effectiveness and safety of anti-inflammatory therapy and/or targeted drug therapy for early treatment of patients with pulmonary arterial hypertension.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
RenJi Hospital
Treatments:
Ambrisentan
Sulfasalazine